Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Hodgson

Data Editor, Pharma

Cambridge, U.K
John is Data Editor, Pharma within Informa’s Pharma Intelligence division. He honed skills as a writer, analyst and consultant, commentating on science and business in biotechnology over three decades. He prefers evidence to received wisdom, and believes that new is interesting but improved is better.
Advertisement
Set Alert for Articles By John Hodgson

Latest From John Hodgson

Stock Scan December 2017: Teva Stick, Valeant Carrot Spur Generics Revival

The end-of-year stock valuations across Big Pharma jumped nearly 3% in December led by financial reassurances at Valeant and gleeful shareholder reaction to ceremonial employee sacrifices at Teva.

Generic Drugs Strategy

Infographic: Scrip 100 Numbers Crunched

This year's Scrip 100 collection is bigger than ever, encompassing 2016 full-year financial data from more than 650 biopharmaceutical companies.

Scrip 100 Sales & Earnings

Scrip 100 Analysis: Sales Up, Profits Down – But Is It Real?

Bellwethers tell you something, but to gauge the health of the pharmaceutical industry, you really need the Scrip 100. For FY 2016, it looks like drug sales are up again and profits are down. But is this what's actually going on?

Scrip 100 Sales & Earnings

Scrip 100 Analysis: Impairment, Youth Boost R&D Spending

Spending on R&D increased substantially in 2016; but the picture is complicated and more than half of the increase is due to accountancy updates following drug program failures, one large company's commitment to new projects, and young companies fuelled by generous financial markets.

Scrip 100 Research and Development Strategies

Stock Scan November 2017: Generics get volatile

Generic drug producers endured very mixed fortunes on the world's stock markets, with firms ending November at opposite ends of Scrip's Stock Scan monthly league table.

Growth Sales & Earnings

Stock Scan October: Generics Pull Pharma Down

Pharma stocks suffered in October, particularly in North America. Across the globe, stock prices among the biggest pharmaceutical companies were down an average of 2% on the month, despite general market revivals in Asia. The generics sector was particularly badly hit but there were several major setbacks for branded pharma companies, too.

Advisory Committees Approvals
See All
Advertisement
UsernamePublicRestriction

Register